

---

# Subject index

- Adjustment
  - for age 70-77
  - for confounders 307-313, 316-318, 361
- Age-adjustment 70-77
- Age-specific rate 66, 71
- Analysis
  - case-control studies 203-208
  - cohort studies 176-182
  - cross-sectional surveys 224-227
  - ecological studies 250-257
  - final 155
  - intention to treat 154
  - matched studies 208
  - on-going 154
  - on randomized treatment 154
  - regression 252, 319-324
  - routine-data-based studies 242-247
  - subgroup 159
  - survival 263-276, 400
- Arithmetic mean, 48
- Attributable risk 97, 356
  
- Bar chart 51
- Baseline data 149, 155
- Bias 143, 277-292
  - diagnostic 210
  - lead-time 373
  - length 372
  - measurement 153, 175, 282-291
  - observer 203
  - recall 203, 287
  - responder 203
  - selection 170, 176, 184, 192, 197, 198, 221, 249, 277-282
  - survival 194
- Biological
  - measurements 16-18
  - plausibility 296
  - samples 173, 183, 417
- Biologically effective dose 14
- Birth cohort analysis 68
  
- Blind techniques
  - double 153
  - single 153
  - unblinding 154
- Blood samples 183, 417
- Box-and-whisker plot 49
  
- Cancer registries 32, 231, 385-403
  - data collection 388-389
  - hospital-based 32, 387, 401-402
  - in developing countries 392-394
  - population-based 32, 385
  - population definition 387
- Case
  - definition 57, 190, 263
  - incident 193
  - prevalent 193
- Case-cohort studies 199
- Case-control studies 7, 88, 189-212
  - analysis 203-208
  - bias 192, 197, 203, 278-281
  - control selection 89, 195-202
  - exposure measurement 203
  - hospital-based 195
  - nested 182, 196
  - of screening 377, 381-383
  - source of cases 195
- Causality 296-299
  - reverse 212
- Cause of death 31, 248
  - misclassification 32
- Cause-specific survival 272
- Censoring 266-268
- Census 65, 249
- Chance 103-118, 294
- Chi-squared test 127-133, 309, 328, 331
  - for linear trend 130-132
- Classification of disease 41-44, 391
- Clinical trial 85, 135
- Cohort studies 6, 86, 164-187
  - bias 170, 175, 176, 184, 281

- historical 172
- prospective 172
- of screening 377
- Committee
  - data-monitoring 154
  - ethical 140, 407
- Community trials 136, 151
- Comparison groups 168
  - external 169
  - internal 168
  - multiple 170
- Compliance 150
- Computers 411-414
  - data entry 45, 421
  - packages for survival analysis 275
- Confidence interval 105, 115, 295
  - for measures of occurrence 119-122
  - for effect measures 122-127, 327-331
  - and study size calculations 335
- Confounding 11, 291-294, 352
  - case-control studies 201
  - cohort studies 174, 184
  - control for 293, 305-325
  - ecological studies 259
  - intervention studies, 143
  - residual 294
  - routine-data-based studies 249
- Consent to participate 140
- Contamination 151
- Controls
  - in case-control study 89, 195-202, 209
  - hospital-based 198, 280-281
  - neighbourhood 197
  - number of 198
  - sampling schemes 199
- Correlation coefficient 251
- Cox's proportional hazards model 324
- Crossover trials 148
- Cross-sectional surveys 90, 213-229
  - analysis 224-227
  - bias 221, 278
  - data collection 224
  - study sample 215-224
- Cumulative rate 76
- Data
  - cancer incidence 32, 248
  - categorical 51
  - checking 46, 422
  - coding 43, 404
  - collection 388-389, 418
  - computer entry 421
  - editing 46, 418
  - items for cancer registries 388-390
  - mortality 31, 248
  - processing 45, 418
  - qualitative 51
  - quality 32, 247, 391
  - quantitative 47
  - recording 418
  - reduction 47
  - routine 31-33, 64, 91-95, 231-262
  - validity 19, 25
  - see also* Misclassification
- Death certification 31, 231, 243
- Denominator 58, 65, 249, 387
  - lacking 77, 393
- Diagnosis 191, 263
  - basis for 389
  - overdiagnosis 374
- Diagnostic bias 210
- Diaries 16
- Dose 13-14
  - biologically effective 14
  - see also* Exposure
- Double-blind 153
- Ecological
  - fallacy 257-259
  - studies 92, 249-260, 376
- Effect modification 314-315, 352
- Eligibility criteria 139
- Employment records 172
- End-point
  - intermediate 19, 152
- Error
  - measurement, 28-30
  - sampling, 103
  - standard, 104, 107, 119
- Ethical considerations 83, 135, 137-138, 407
  - see also* Informed consent
- Excess fraction 98, 357, 381
- Excess risk 97, 356, 381
- Exposure 3, 12
  - biological measurements 16
  - cumulative 14
  - environmental measurements 18
  - measurement 13-18, 171-174, 203, 260
  - misclassification 282-289
  - rate 14

- reduction 356, 362-364
- sources of data 14-18
- Exposure-response relationship 179, 180, 206, 297
- Factorial design 147
- Field trial 86, 135
- Fisher's exact test 133
- Follow-up 157, 176
  - in cancer registration 388, 394
  - loss to 154, 176, 282, 352
  - in survival studies 268
- Frequency matching 202
- Funding for projects 405-409
- Geographical variation 231
- Gold standard 22
- Graphs 54
  - bar chart 51
  - box-and-whisker plot 49
  - histogram 48
  - scatter diagram 252
- Healthy worker effect 170, 249, 282
- High-risk groups 378
- Histogram 48
- Hospital-based cancer registry 32, 385, 401-402
- Hypothesis 190
  - null 111, 127, 335
  - testing 115
- Identifiers, personal 33
- Incidence 60
  - age-specific 66, 71
  - cancer 32, 248
  - crude 66
  - date 388
  - proportional 78
  - rate 62-63
  - ratio, proportional 78
  - ratio, standardized, 75
- Individual matching 200, 208
- Induction period *see* Latent period
- Informed consent 140
- Intention-to-treat analysis 154
- Interaction 314-315, 352
- Intermediate end-point 19, 152
- International Classification of Diseases 5, 42-44
- International Classification of Diseases for Oncology (ICD-O)  
43, 391
- Inter-observer reliability 25-27
- Intervention studies 8, 83, 84-87, 135-162
  - bias 282
  - of cancer treatment 379
  - of screening 375
- Interview 15
- Intra-observer reliability 25
- Kaplan-Meier survival analysis 270
- Kappa statistic 25
- Laboratory measurements 17, 31, 416
- Latent period 172, 176, 260
- Lead time 373
- Lexis diagram 67
- Life table 269
- Linkage, record 33, 241
- Logistic regression 320-324
  - conditional 324
- Loss to follow-up 154, 176, 282, 352
- Mantel-Haenszel analysis 127, 307-313
  - multiple confounders 316-318
  - odds ratio 308, 316, 327
  - rate ratio 311, 330
  - risk ratio 309, 329
- Manual of Tumor Nomenclature and Coding  
(MOTNAC) 42
- Markers, exposure 17
- Masking 153
- Matched pair design 146
- Matched studies
  - analysis 208
- Matching 200, 293
  - frequency 202
  - individual 200, 208
- Mean
  - arithmetic 48
  - sample 107
  - standard error 107
- Measurement
  - bias 153, 175, 184, 282-291
  - biological 16-18
  - confounding variables 174
  - environmental 18
  - error 28-30
  - exposure 13-14, 171-174, 203
  - outcome 18-19, 175
- Median 48
- Meta-analysis 300
- Migrant studies 232-238, 282

- Misclassification
  - cause of death 32
  - differential 30, 286-291
  - disease 191, 196
  - exposure 282-289
  - non-differential 29, 284-286, 290
  - outcome 290-291
- Molecular epidemiology 17
- Mortality
  - data 31, 248
  - ratio, proportional 78
  - ratio, standardized, 75
- Multicentric studies 203
  
- Neighbourhood controls 197
- Nested case-control studies 182, 196
- Normal distribution 50, 335
- Null hypothesis 111, 127, 335
- Numerator 57, 249
- Nutritional studies 183
  
- Observational studies 83-84, 375
- Observer bias 203
- Occupational studies 167, 172, 238, 281, 291
- Odds
  - of disease 61
  - of exposure 205
  - ratio 95, 205-208, 225, 244, 308, 316, 327
- Outcome 11, 152, 264
  - measurements 18-19, 175
  - misclassification 290-291
- Outliers 49
- Overdiagnosis 374
- Overmatching 197, 201
  
- P*-value 111-117, 294, 334
- Percentiles 49
- Person-time at risk 62, 64, 177, 243
- Placebo 142, 153
- Poisson regression 322
- Pooling 300
- Population 2
  - at risk 58
  - attributable risk 359
  - excess fraction 359, 381
  - excess risk 359, 381
  - experimental 139
  - general 166
  - highly exposed 167
  - samples 103, 215
  - source 215
  - standard 72, 81
  - study 141, 166
  - target 138, 215
- Population-based cancer registry 32, 385-403
- Power, statistical 167, 192, 198, 334-343
- Precision, sample size calculations 343
- Pre-clinical disease 355, 366
- Predictive value 20, 367, 371
- Prevalence 58, 63, 90, 224
- Prevented fraction 98, 159, 358
- Prevention 8, 355-380
  - primary 355, 356-365, 400
  - secondary 355, 365-379, 400
  - tertiary 356, 379, 399
- Probability
  - of dying 266, 268
  - of surviving 268
  - P*-value 111-117, 294, 334
- Proportional incidence ratio (PIR) 78, 244
- Proportional mortality ratio (PMR) 78, 244
- Protocol, study 30, 405-407
- Proxy
  - respondent 15
  - variables 173
- Pseudo-cancer 374
- Publication 423
  
- Quality
  - control, laboratory 31, 416
  - data 32, 247, 391
  - indicators 32
- Quartiles 49
- Questionnaires 14
  - design 35-38
  - evaluation 38
  - interviewer-administered 15
  - self-administered 15
  - standard 39
  
- Random
  - allocation 142-150
  - numbers 163
  - sampling 103, 216-221
- Randomization 84, 143, 293, 375
  - blocked 145
  - matched-pair 146
  - restricted 145
  - simple 144, 216
  - stratified 146, 220

- Randomized trials *see* Intervention studies
- Rate ratio 95, 206  
Mantel-Haenszel 311, 330  
standardized 73
- Recall bias 203, 287
- Receiver operating characteristic (ROC) curve 23
- Record linkage 33, 241
- Refusal 149, 352
- Registration *see* Cancer registries
- Regression analysis 252, 319-324  
logistic 320  
Poisson 322
- Reliability 25-27, 367
- Repeatability 25
- Reproducibility 25
- Responder bias 203
- Reverse causality 212
- Risk 60, 64  
attributable 97, 356  
difference 97  
excess 97, 356  
factor 3  
ratio 95, 206, 309, 329  
reduction 98, 358  
relative 95
- Routine data 31, 64, 175
- Routine-data-based studies 91-95, 231-262  
aggregated level 249-260  
analysis 242-247, 250-257  
individual level 231-249
- Sample  
biological 173, 183, 417  
of population 103, 215  
random 103  
size calculation 333-353
- Sampling  
for controls 199  
distribution 103  
environmental measurements 18  
error 103  
frame 216  
multi-stage 218  
random 103, 216-221  
stratified random 220  
systematic 218
- Scatter diagram 252
- Screening 355, 365-379  
effectiveness 372-374  
evaluation 370-378, 400  
monitoring 241  
population 369
- Secondary prevention 355, 365-379, 398
- Selection bias 277-282  
in case-control studies 192, 197, 198, 278-281  
in cohort studies 165, 170, 171, 179, 281  
in cross-sectional surveys 221  
in randomized trials 282  
in routine-data-based studies 249
- Sensitivity 19-24, 368
- Side-effects 150
- Significance test 111  
*see also* Statistical significance
- Size of study 333-353
- Socioeconomic status 238-239
- Specificity 20, 368
- Standard deviation 50  
of sampling distribution 104
- Standard error 104, 107, 119, 335
- Standard populations 72, 81
- Standardization 71  
direct 72  
indirect 74
- Standardized incidence ratio (SIR) 75, 182
- Standardized mortality ratio (SMR) 75, 182
- Statistical  
power 167, 192, 198, 334-343  
significance 112-114, 294, 334  
testing 127-133, 328, 331
- Stratification 66, 67, 294, 305-307
- Stratified randomization 146, 220
- Study design 83-101  
*see also* Case-control studies, Cohort studies,  
Cross-sectional surveys, Intervention studies,  
Routine-data-based studies
- Study population  
for cohort study 166  
for cross-sectional survey 215  
for intervention trial 137
- Study size 333-353
- Surrogate respondent 15
- Survival  
analysis 263-276, 400  
bias 194  
cause-specific 272  
censoring 266-268  
probability 268-269  
time 266  
trends 400

- Tables 53
- Target population 138, 215
- Tertiary prevention 356, 379, 399
- Test *see* Statistical significance
- Time trend 66-70, 239, 248, 400
- Treatment 366, 369, 379
- Trend
  - survival 400
  - time 66-70, 239
  - with exposure level 179
  - with exposure duration 180
- Unblinding 154
- Vaccine efficacy 159
- Validity 19, 25, 367
- Variance 50
- Volunteers 139, 278
- Withdrawal 149, 154, 282







---

Achevé d'imprimer sur rotative  
par l'Imprimerie Darantière à Dijon-Quetigny  
en décembre 2010

Dépôt légal : juin 2002  
N° d'impression : 10-1688

